CJC-1295 DAC

Source type: Human study. Sources checked 2026-11-12.

What the cited research examined

Two placebo-controlled studies examined prolonged GH and IGF-I responses in healthy adults.

These pharmacokinetics apply to the long-acting study compound, not products labeled “CJC-1295 no DAC” or Mod GRF(1-29).

Reference facts

Half-life

5.8–8.1 daysEstimated in healthy adults after subcutaneous administration of the long-acting, albumin-binding study formulation. Not a dosing interval.

Human dose range

Not provided. This reference does not recommend a human dose.

Administration interval

Not established by these sources. A half-life is not a dosing schedule.

Storage

Product-specific information required. These sources do not establish a storage specification.

Safety context

FDA reports cardiovascular events and limited available clinical data.

Research results and substance listings are not product approvals. The FDA overview distinguishes current Category 2 entries from withdrawn nominations; withdrawal does not establish safety.

Sources and review method

1. Placebo-controlled healthy-adult studies
2. Characterization of the albumin-binding compound
3. FDA: bulk substances with potential safety risks (includes withdrawn nominations)

These are bounded summaries of the linked sources, not systematic reviews. An unknown field means that these sources do not establish a general-use value. It does not claim that no other literature exists.